SSSW(SH:688399)2021-03-25 16:00Financial Performance - The company reported a total revenue of RMB 1.5 billion for the year 2019, representing a year-over-year growth of 20%[13]. - The company's operating revenue for 2020 reached ¥1,739,680,701.97, representing a 502.39% increase compared to ¥288,794,709.93 in 2019[25]. - Net profit attributable to shareholders increased by 878.52% to ¥819,567,339.93 from ¥83,756,179.76 in the previous year[25]. - The net cash flow from operating activities rose by 776.96% to ¥935,881,451.61, up from ¥106,718,818.92 in 2019[25]. - Basic and diluted earnings per share increased by 655.68% to ¥13.98 from ¥1.85 in 2019[26]. - The weighted average return on equity rose by 39.98 percentage points to 60.06% from 20.08% in the previous year[26]. - Total assets grew by 97.31% to ¥2,277,673,271.40 from ¥1,154,362,463.82 in 2019[25]. - The net assets attributable to shareholders increased by 63.06% to ¥1,664,496,808.80 from ¥1,020,789,468.87 in 2019[25]. - The company's revenue growth was primarily driven by increased demand for COVID-19 testing products due to the pandemic[27]. - In 2020, the company achieved a total revenue of 1,739.68 million RMB, representing a growth of 502.39% compared to the previous year[72]. - The net profit attributable to the parent company reached 819.57 million RMB, an increase of 878.52% year-on-year[72]. Research and Development - Investment in R&D for new diagnostic technologies increased by 30%, focusing on molecular diagnostics and immunodiagnostics[14]. - Total R&D expenditure increased significantly to ¥72,065,668.48, representing an 86.90% growth compared to the previous year[54]. - The company focused on enhancing R&D during the pandemic, which contributed to the substantial increase in R&D investment[55]. - The company has 104 R&D personnel, making up 18.12% of the total workforce, with 50% holding master's degrees or higher[65]. - The company aims to optimize product lines and enhance clinical efficiency through ongoing R&D efforts[57]. - The company is expanding its product offerings to meet the growing market demand for infectious disease testing solutions[57]. - The company plans to enhance its product performance by adopting fluorescence immunoassay technology for disease marker detection[9]. - The company has developed over 500 products, covering infectious disease prevention, clinical testing, large-scale population screening, and reproductive health management[48]. Market Expansion and Strategy - The company expects a revenue growth of 25% for the upcoming fiscal year, driven by new product launches and market expansion strategies[13]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[13]. - The company is actively developing non-COVID products such as HPV and BV testing reagents to mitigate the impact of the pandemic[71]. - The company aims to leverage the "Internet+" opportunity to advance online hospital construction and actively expand into the home-based in vitro diagnostic market[46]. - The company is focusing on increasing the R&D and production scale of core raw materials to capture new profit growth points[81]. - The company plans to enhance its marketing network by optimizing distributor management and expanding direct sales to improve service capabilities[121]. Corporate Governance and Risk Management - The board of directors has confirmed the authenticity and completeness of the annual report, ensuring accountability for any misrepresentation[4]. - The company has outlined various operational risks and corresponding mitigation strategies in the report, emphasizing the importance of risk management[4]. - There are no reported instances of non-operational fund occupation by controlling shareholders or related parties[7]. - The company does not have any special arrangements for corporate governance that would affect the report's integrity[6]. - The company has not violated any decision-making procedures regarding external guarantees[7]. - The company has implemented strict confidentiality measures to protect its core technologies, which are crucial for maintaining competitive advantages[76]. - The company is exposed to macroeconomic risks, particularly regarding the supply of raw materials sourced from overseas amid a complex international trade environment[80]. Shareholder Rights and Profit Distribution - The company plans to distribute cash dividends of at least 40% of profits for mature stages and at least 20% for growth stages when significant capital expenditures are involved[127]. - The company is committed to protecting shareholder rights and will communicate with minority shareholders before profit distribution proposals are reviewed[128]. - The company has a mechanism for adjusting profit distribution policies in response to significant changes in external operating environments or internal conditions[128]. - The company will ensure that any cash dividends distributed will not be less than 30% of the distributable profits for the year[148]. - The company will provide clear explanations for any cash dividend distributions that are lower than expected, including industry characteristics and funding needs[148]. - The company emphasizes the importance of maintaining sufficient cash flow and funding needs when planning dividend distributions[148]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants, indicating a clean financial audit[4]. - The company guarantees that its financial documents for the initial public offering do not contain false statements or omissions, taking legal responsibility for their accuracy[149]. - The company will ensure compliance with regulatory requirements regarding the accuracy of its financial disclosures to protect investor interests[149]. - The company has committed to minimizing related party transactions and ensuring fair pricing in unavoidable cases[162]. Product Development and Innovation - The company has successfully developed a COVID-19 nucleic acid detection reagent in response to the pandemic, significantly increasing production capacity[70]. - The company has launched antigen testing kits for H1N1/H3N2 influenza viruses in the POCT field, generating revenue from these products[142]. - The company has introduced advanced instruments for intelligent and standardized detection of female reproductive tract microecology, improving diagnostic levels in resource-limited areas[142]. - The company is focusing on the integration of diagnostic reagents and instruments, aiming for a fully automated testing process with "sample in, result out" capabilities[143]. Financial Management - The company reported a total of 21,000.00 million RMB in structured deposits as of December 2020, with an annualized return of 3.70%[173]. - The company has ongoing lease agreements with various entities, including a lease amount of 9,000,000 RMB starting from November 13, 2018, to November 12, 2023[166]. - The company has a total of 4,000.00 million RMB in structured deposits with an annualized return of 3.75% as of March 2020[173]. - The total amount of raised funds is CNY 612,933,570, with CNY 67,003,975.53 invested in the current year[179].